Globus Medical Inc (GMED)
$55.35 1.10 (1.95%)
18:29 EST GMED Stock Quote Delayed 15 Minutes
Previous Close $55.35
Market Cap 4.06B
PE Ratio 46.51
Volume (Avg. Vol.) 921,200
Day's Range 52.40 - 56.01
52-Week Range 38.37 - 60.15
Dividend & Yield N/A (N/A)
GMED Stock Predictions, Articles, and Globus Medical Inc News
- From InvestorPlace
- From the Web
Thankfully, the start to 2019 has been much better than 2018's end. Here are seven stocks to buy that are due for a comeback this year.
Companies in the medical appliances and equipment market of spines are sharply above yearly lows. Analyst coverage in the spinal stock sector is giving those stocks a temporary boost.
This week, 12 Health Care Equipment & Supplies stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, the overall grades of 21 Health Care Equipment & Supplies stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The fiscal responsibility of these seven stocks to buy will soon be rewarded when they eat well and Wall Street's grasshoppers starve.
Globus Medical, Inc. Yearly Results Just Came Out: Here’s What Analysts Are Forecasting For Next Year
From Simply Wall St
Last week, you might have seen that Globus Medical, Inc. (NYSE:GMED) released its annual result to the market. The early response was not positive, with shares down 2.1% to US$55.35<div><a class="permalink" href="https://simplywall.st/stocks/us/healthcare/nyse-gmed/globus-medical/news/globus-medical-inc-yearly-results-just-came-out-heres-what-analysts-are-forecasting-for-next-year/">Read More...</a></div>
From Analyst Ratings
Oppenheimer analyst Steven Lichtman maintained a Hold rating on Globus Medical (GMED – Research Report) today and set a price target of $60.00. The company’s shares closed last Monday at $56.45. According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.7% and a 51.1%
Analysts Are Bullish on These Healthcare Stocks: Bioxcel Therapeutics (BTAI), Atara Biotherapeutics (ATRA)
From Analyst Ratings
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report), Atara Biotherapeutics (ATRA – Research Report) and Globus Medical (GMED – Research Report) with bullish sentiments. Bioxcel Therapeutics (BTAI) Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Bioxcel Therapeutics
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader